Lupin Limited (NSE:LUPIN)
2,267.30
-5.80 (-0.26%)
Jun 16, 2026, 10:45 AM IST
Lupin Revenue
In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B INR with 23.12% growth. Lupin had revenue of 74.75B in the quarter ending March 31, 2026, with 31.89% growth.
Revenue
279.58B
Revenue Growth
+23.12%
P/S Ratio
3.72
Revenue / Employee
11.65M
Employees
24,006
Market Cap
1.04T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 336.53B |
| Cipla | 278.28B |
| Zydus Lifesciences | 271.48B |
| Glenmark Pharmaceuticals | 169.83B |
| Alkem Laboratories | 147.12B |
| Mankind Pharma | 142.78B |
| Divi's Laboratories | 105.60B |
| Ipca Laboratories | 96.46B |
Lupin News
- 7 days ago - Lupin collaboraters with Spain’s ERN to launch Luforbec for Asthma and COPD treatment - Business Upturn
- 11 days ago - Lupin Wins FDA Approval For Ranluspec Biosimilar To Lucentis - Nasdaq
- 12 days ago - Lupin And Natco Receive FDA Approval For Eribulin Mesylate Injection - Nasdaq
- 12 days ago - Natco Pharma and Lupin secure U.S. FDA approval for Eribulin Mesylate Injection - Business Upturn
- 17 days ago - Lupin Receives U.S. FDA Approval For Generic Sutab Tablets - Nasdaq
- 24 days ago - Lupin Secures China Approval For Oseltamivir Oral Suspension, Marking Its Market Debut - Nasdaq
- 5 weeks ago - Lupin Transcript: Q4 25/26 - Transcripts
- 5 weeks ago - Lupin Quarterly report: Q4 2026 - Filings